Menopausal Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Menopausal Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Menopausal disorders encompass a range of symptoms and health issues that arise during and after menopause, a natural biological process marking the end of a woman’s reproductive years. Common menopausal symptoms include hot flashes, night sweats, mood swings, and changes in sleep patterns. Hormonal fluctuations during this transition can also lead to conditions such as vaginal atrophy, affecting the genital tissues, and osteoporosis, a loss of bone density. Additionally, menopausal women may experience challenges related to sexual health and emotional well-being. Management often involves hormone replacement therapy, lifestyle modifications, and medications to address specific symptoms and reduce long-term health risks associated with hormonal changes. Regular medical check-ups and open communication with healthcare providers play a crucial role in navigating menopausal disorders effectively.
The Menopausal Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Menopausal Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Menopausal Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Menopausal Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 26 molecules, with 25 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Menopausal Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Menopausal Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Menopausal Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acrux LtdAstellas Pharma Inc
Bayer AG
Besins Healthcare SA
Chong Kun Dang Pharmaceutical Corp.
Cosette Pharmaceuticals Inc
Dare Bioscience Inc
Eli Lilly and Co
Endoceutics Inc
Estrigenix Therapeutics Inc
Fervent Pharmaceuticals LLC
Gameto Inc
Iaterion Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Korea Pharma Co Ltd
MenoGeniX Inc
Mithra Pharmaceuticals SA
Mitsubishi Tanabe Pharma Corp
Oregon Health & Science University
Pfizer Inc
Que Oncology Inc
TherapeuticsMD Inc
Viramal Ltd
VistaGen Therapeutics Inc
Zharko Pharma Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Menopausal Disorders reports